Pharmaceutical

EC approves BMS’ Camzyos for hypertrophic cardiomyopathy

The European Commission has approved Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy.

Jun 27, 2023 - 20:00
EC approves BMS’ Camzyos for hypertrophic cardiomyopathy
The European Commission has approved Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy.
Read the original article

Tags:

Previous Article

Tonix to acquire Upsher-Smith’s migraine products

Next Article

Vertex and Lonza to establish T1D cell therapy manufacturing facility

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

EMA starts review into hair loss drugs about potential link to suicidal thoughts 

EMA starts review into hair loss drugs about potential ...

Oct 8, 2024

Evox Therapeutics teams with New York medical school to co-develop AAV vectors

Evox Therapeutics teams with New York medical school to...

Aug 4, 2023

STAT+: Study proposing microbiome-based cancer diagnostic comes under fire

STAT+: Study proposing microbiome-based cancer diagnost...

Aug 3, 2023